Results 1 to 10 of about 11,528 (105)

Differences between therapeutic mechanisms of resmetirom and semaglutide against MASH in western diet-fed MC4R-knockout mice [PDF]

Scientific Reports
Metabolic dysfunction-associated steatotic liver disease (MASLD) can progress to steatohepatitis (MASH), which is closely associated with obesity and insulin resistance. Resmetirom, and semaglutide, have been shown to have therapeutic effects in clinical
Takumi Sugawara, Kosuke Hitaka, Mitsuharu Matsumoto, Sayuri Nakamura, Ryosuke Kobayashi, Hitoshi Kandori, Yasunori Nio   +6 more
doaj   +2 more sources

Glucagon-like peptide-1 receptor agonist in large vessel occlusion treated by reperfusion therapy—a phase 2 randomized trial [PDF]

Nature Communications
We aimed to determine the effect of semaglutide on patients with acute large vessel occlusion (LVO) receiving endovascular therapy (EVT). In this phase 2, investigator-initiated, multicenter, prospective, randomized, open-label, blinded endpoint trial ...
Hao Wang, Ho Ko, Thomas W. Leung, Junzhe Huang, Junjie Sai, Yu Liang, Haipeng Li, Jie Zhang, Qingyang Cao, Wentao Zang, Yinfei Li, Sze Ho Ma, Wai Ting Lui, Joseph Choi, Charlie Chan, Jason Wong, Andrew J. Kwok, Karen Ma, Florence Fan, Anne Chan, Vincent Ip, Howan Leung, Yannie Soo, Ka Tak Wong, Billy Lai, CM Chu, Ho Sang Leung, Anselm Hui, Tom Cheung, Jill Abrigo, Siu Hung Li, Larry Chan, Jonas Yeung, Sangqi Pan, Terry Yip, LT Lui, Trista Hung, Suk Fung Tsang, Xinyi Leng, Bonnie Lam, Vincent C. T. Mok, Rosa H. M. Chan, Thanh N. Nguyen, Wei Hu, Fengyuan Che, Bonaventure Y. Ip   +45 more
doaj   +2 more sources

The efficacy and safety of oral semaglutide for glycaemic management in adults with type 2 diabetes compared to subcutaneous semaglutide, placebo, and other GLP-1 RA comparators: A systematic review and network meta-analysis

Contemporary Clinical Trials Communications, 2022
Aim: Semaglutide is a long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA) indicated for glycaemic management in adults with type 2 diabetes (T2D).
Yousef Alhindi, Amanda Avery
doaj   +1 more source

Exploring the Appropriate Price of Semaglutide for Type 2 Diabetes Patients Based on Cost-Utility Analysis in China

Frontiers in Pharmacology, 2021
Introduction: Semaglutide is the first and only oral version of a glucagon-like peptide-1 analogue approved by the FDA for the treatment of type 2 diabetes (T2D). This research was designed to explore the appropriate price of once-weekly (OW) semaglutide
Shanshan Hu, Shanshan Hu, Xiaorong Su, Xun Deng, Xun Deng, Yong Wang, Yong Wang   +6 more
doaj   +1 more source

Case Report: Semaglutide-associated depression: a report of two cases

Frontiers in Psychiatry, 2023
Semaglutide, as a glucagon-like peptide-1 receptor agonist (GLP-1 RA), was approved for glucose control in type 2 diabetes mellitus in 2017 and approved for weight loss in 2021 by the U.S. Food and Drug Administration (FDA). No psychiatric adverse effect
Jia-Rui Li, Jinya Cao, Jing Wei, Wenqi Geng   +3 more
doaj   +1 more source

Semaglutide reduces alcohol intake and relapse-like drinking in male and female ratsResearch in context

EBioMedicine, 2023
Summary: Background: Glucagon-like peptide1 receptor (GLP-1R) agonists have been found to reduce alcohol drinking in rodents and overweight patients with alcohol use disorder (AUD).
Cajsa Aranäs, Christian E. Edvardsson, Olesya T. Shevchouk, Qian Zhang, Sarah Witley, Sebastian Blid Sköldheden, Lindsay Zentveld, Daniel Vallöf, Maximilian Tufvesson-Alm, Elisabet Jerlhag   +9 more
doaj   +1 more source

Population pharmacokinetic of paracetamol and atorvastatin with co‐administration of semaglutide

Pharmacology Research & Perspectives, 2022
Semaglutide is a glucagon‐like‐peptide‐1 (GLP‐1) analogue marketed for once‐weekly subcutaneous administration for type 2 diabetes mellitus. Like other long‐acting GLP‐1 analogues, semaglutide reduces gastric emptying and, potentially, alters the rate of
Emilie K. Langeskov, Kim Kristensen
doaj   +1 more source

Comparative Cardio-Renal Outcomes of Type 2 Diabetes Patients Administered Glucagon-Like Peptide-1 Receptor Agonists: A Network Meta-Analysis

Frontiers in Pharmacology, 2021
Background: Cardio-renal profiles are available from cardiovascular outcome trials of glucagon-like peptide-1 receptor agonists (GLP-1 RAs).Methods: A comprehensive systematic review of Embase, Medline, Web of Knowledge, and CENTRAL databases was ...
Chuanjun Zhuo, Chuanjun Zhuo, Chuanjun Zhuo, Chuanjun Zhuo, Chongguang Lin, Chunhua Zhou, Xiangyang Gao, Hailin Shao, Tao Fang, Hongjun Tian, Li Ding, Ming Liu   +11 more
doaj   +1 more source

Effects of the Topical Administration of Semaglutide on Retinal Neuroinflammation and Vascular Leakage in Experimental Diabetes

Biomedicines, 2021
Background: An unexpected increase in the rate of severe diabetic retinopathy was observed in the Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN)-6 clinical trial.
Rafael Simó, Patricia Bogdanov, Hugo Ramos, Jordi Huerta, Olga Simó-Servat, Cristina Hernández   +5 more
doaj   +1 more source

Safety of Semaglutide

Frontiers in Endocrinology, 2021
The glucagon-like peptide-1 receptor agonist (GLP-1RA) semaglutide is the most recently approved agent of this drug class, and the only GLP-1RA currently available as both subcutaneous and oral formulation.
Mark M. Smits, Daniël H. Van Raalte
doaj   +1 more source